Skip to main content

Pharmaceutical Manufacturing AI: GMP Compliance Through Governance

Manufacturing teams in pharma want AI for batch-record summarization, deviation drafting, SOP search, CAPA assistance, and change-control preparation. Those are sensible use cases because they remove slow manual text work from high-volume quality systems. They also introduce a classic GxP problem: if AI output influences release, deviation closure, or procedural interpretation, you need a control model that is more rigorous than “the system saves time.” Keeptrusts helps by enforcing rbac, data-routing-policy, quality-scorer, human-oversight, safety-filter, and audit-logger around the text workflows that sit next to GMP operations.

Use this page when​

  • You are introducing AI into batch review, deviation management, SOP retrieval, or CAPA workflows.
  • You need a governance layer that preserves traceability and review requirements in GMP-regulated environments.
  • You want to prevent manufacturing assistants from turning into unreviewed release or quality-decision tools.

Primary audience​

  • Primary: Technical Leaders
  • Secondary: Technical Engineers, Manufacturing quality and validation teams

The problem​

Pharma manufacturing AI rarely fails because the text is obviously bad. It fails because the organization cannot prove how the text was produced, what it influenced, or where review actually occurred. A summary of a batch deviation may look harmless until it becomes the basis for a quality decision. A search assistant may look low risk until operators start treating its SOP interpretation as authoritative. In GMP environments, hidden influence is its own governance issue.

There is also a boundary problem with data handling. Batch records, equipment events, environmental excursions, and deviation notes may contain internal identifiers, proprietary process details, and investigator commentary that should not leave an approved provider path. That is especially important when organizations are mixing internal quality systems with external AI vendors.

Finally, manufacturing teams need durable evidence. If QA or an inspector asks how AI was used in a deviation narrative or CAPA draft, the organization should be able to point to an event trail, a route policy, and a human review step. That is much stronger than trying to reconstruct behavior from disconnected application logs.

The solution​

The best design is to keep manufacturing AI assistive and review-centered. rbac ensures only named users and roles can drive the route. data-routing-policy restricts the provider set so internal manufacturing content only reaches approved targets. quality-scorer helps reject shallow or incomplete output before it enters a GMP workflow. safety-filter blocks language that sounds like unreviewed product release, process suitability certification, or other unsupported manufacturing conclusions. human-oversight then stops the high-impact outputs that must be reviewed.

audit-logger is the essential control because regulated manufacturing depends on record quality as much as prompt quality. If the event trail is incomplete, the route is hard to defend even when the text looked reasonable.

For background, use Pharmaceutical, Regulated Execution, and the Policy Controls Catalog. The practical rule is to make the AI route visibly subordinate to GMP review. It can draft, summarize, and prepare. It should not quietly approve, release, or close.

Implementation​

This route keeps manufacturing assistants on approved providers and escalates outputs tied to release or deviation closure.

pack:
  name: pharma-manufacturing-governance
  version: 1.0.0
  enabled: true

providers:
  targets:
    - id: local-gxp-model
      provider: ollama
      model: llama3.1:70b
      base_url: http://localhost:11434
    - id: openai-zdr-quality
      provider: openai
      model: gpt-5.4-mini-mini
      secret_key_ref:
        env: OPENAI_API_KEY
      data_policy:
        zero_data_retention: true
        training_opt_out: true
        retention_days: 0

policies:
  chain:
    - rbac
    - data-routing-policy
    - safety-filter
    - quality-scorer
    - human-oversight
    - audit-logger

policy:
  rbac:
    deny_if_missing:
      - X-User-ID
      - X-User-Role

  data-routing-policy:
    require_zero_data_retention: true
    on_no_compliant_provider: block
    log_provider_selection: true

  safety-filter:
    action: block

  quality-scorer:
    thresholds:
      min_aggregate: 0.85

  human-oversight:
    require_human_for:
      - batch-release-summary
      - deviation-root-cause-draft
      - capa-closeout-recommendation
    action: escalate

  audit-logger:
    immutable: true
    retention_days: 3650

This route is deliberately conservative. Even if a local model is available, the system still records the route and applies review stops. That matters because GMP governance is not just about external-data exposure. It is also about proving where AI entered the workflow and which outputs required human sign-off.

To operate it cleanly, manage the route through Configurations, review evidence exports with Tutorial: Exporting Compliance Evidence, and use Reviewing Alerts and Evidence when QA wants to sample how the route behaved during a validation window.

Results and impact​

Manufacturing teams get faster draft generation without weakening GMP control points. Deviation writers, reviewers, and quality engineers spend less time on repetitive narrative work, but the organization does not have to blur the line between AI assistance and validated decision-making. That distinction is what makes adoption durable.

There is also a governance payoff: route ownership becomes clear. Quality, validation, and platform teams can agree on one control pattern for manufacturing text workflows instead of negotiating every assistant separately. That reduces review overhead and improves inspection readiness.

Key takeaways​

  • Keep manufacturing AI in a drafting and summarization lane, not a release-decision lane.
  • Use data-routing-policy to keep GMP-sensitive content on approved providers.
  • Use quality-scorer and safety-filter so weak or unsafe text does not flow downstream.
  • Use human-oversight for release, deviation, and CAPA-adjacent outputs.
  • Preserve inspection-ready evidence with audit-logger.

Next steps​